Success Stories: EB1A Approval Granted to Cardiovascular Disease Researcher Despite RFE
Client’s Testimonial:
“Thank you for all your help and guidance.”
On May 1st, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an Interventional Cardiologist in the Field of Cardiovascular Disease (Approval Notice).
General Field: Cardiovascular Disease
Position at the Time of Case Filing: Interventional Cardiologist
Country of Origin: India
State of Residence at the Time of Filing: Arizona
Approval Notice Date: May 1st, 2025
Processing Time: 3 months, 28 days (Premium Processing Requested)
Case Summary: We are pleased to announce the approval of an I-140 petition under the EB1A (Alien of Extraordinary Ability) category for a distinguished cardiovascular researcher originally from India. Despite receiving a Request for Evidence (RFE), our strategic and evidence-rich response led to a favorable decision issued on May 1, 2025 — just under four months from the original filing date of January 3, 2025.
Our client is a leading figure in interventional cardiology, with extensive work on coronary artery disease, structural heart disease, and cardiovascular care during pandemics. His cutting-edge research has contributed to enhanced treatments for coronary complications, improved interventional techniques, and innovative therapeutic strategies addressing cardiac risks during public health emergencies.
Currently working in the United States as a practicing interventional cardiologist, he continues to drive forward the development of safer, minimally invasive cardiovascular interventions with a focus on improving long-term patient outcomes.
To support this petition, we presented a robust record of achievement:
● Publications: 81 peer-reviewed journal articles and 49 conference abstracts.
● Citations: His work has been cited over 1,110 times, placing him among the top 1% most-cited researchers in cardiovascular medicine.
● Review Service: Over 100 peer reviews for top journals such as JACC: Cardiovascular Interventions and Circulation: Cardiovascular Quality and Outcomes.
● Editorial Roles: Board member for respected cardiology journals.
● Recognition: Numerous invited talks and speaking engagements at major international cardiovascular conferences.
● Research Funding & Impact: His published work has informed major clinical trials, national treatment guidelines, and global cost-benefit models in cardiac care.
One of the supporting recommendation letters noted:
“Dr. [Client]’s work on drug-coated balloon therapies and structural interventions has shaped modern clinical approaches and trial designs, helping physicians worldwide improve outcomes for high-risk cardiovascular patients.”
To demonstrate his significance, we documented how:● His findings have been implemented in clinical trials, multinational treatment protocols, and public health strategies.
● Multiple publications rank among the top 10% most-cited for their publication years in clinical medicine.
● His innovative techniques — including micropuncture access and advanced imaging for stent restenosis — are now considered standard references in interventional cardiology literature.
Our detailed petition addressed both prongs of the EB1A final merits determination, providing extensive independent citations, evidence of peer recognition, and proof of sustained international acclaim.This approval, especially in the face of an RFE, underscores both the outstanding nature of our client’s contributions and the effectiveness of a well-structured petition. We are honored to have supported this accomplished physician-scientist and look forward to his continued success as a leader in cardiovascular medicine in the U.S.